BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Brekiya® (dihydroergotamine mesylate) injection. This marks the introduction of the first and only DHE autoinjector designed for the acute treatment of migraine with or without aura and cluster headaches in adults. The innovative autoinjector allows patients to self-administer the medication, traditionally used in hospitals, in a ready-to-use form. Brekiya will be available for appropriate patients in the second half of 2025, providing a convenient option for those seeking quick relief from these debilitating conditions without needing to visit an emergency room.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.